Reforms set to generate up to €1.4 billion in value for reinvestment in the Irish healthcare system Medicines for Ireland (MFI), the representative body for
New agreement set to unlock earlier access to generic, biosimilar and value-added medicines tostrengthen supply chains, secure access for Irish patients, and deliver value for
Generic, biosimilar and value-added medicines industry leadership reinforced as it prepares for the next framework agreement on pricing and supply of medicines and responds to
We are committed to working with key stakeholders to affect real change and reforms that ensure Irish patients receive the best medical treatment in the most affordable way.
